Back to Search
Start Over
Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent
- Source :
- ecancermedicalscience
- Publication Year :
- 2016
- Publisher :
- Ecancer Global Foundation, 2016.
-
Abstract
- Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
medicine.drug_class
Context (language use)
Propranolol
beta-blockers
03 medical and health sciences
0302 clinical medicine
Immune system
Internal medicine
medicine
Repurposing
Metastatic cascade
drug repurposing
business.industry
Cancer
ReDO project
medicine.disease
Receptor antagonist
Drug repositioning
030104 developmental biology
030220 oncology & carcinogenesis
Clinical Study
business
medicine.drug
Subjects
Details
- ISSN :
- 17546605
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- ecancermedicalscience
- Accession number :
- edsair.doi.dedup.....74550884f6eb50a21dfec2801fb646f8